ForeseeHOME

Early wet AMD detection with ForeseeHome®

Physicians' Perspective


Detecting wet AMD at the earliest possible moment is critical to long-term visual outcomes; baseline visual acuity is the strongest predictor of long-term visual acuity. Unfortunately, too few patients present with functional vision, ≥20/40, at the time of wet AMD diagnosis, which may lead to a poor prognosis.

Drs. Joseph Coney and Veeral Sheth discuss their experience with the ForeseeHome AMD monitoring program, the only FDA cleared, Medicare covered, at-home monitoring program proven to help detect wet AMD at the earliest possible moment.1 Learn how ForeseeHome detected wet AMD early and helped Drs. Coney and Sheth protect and preserve the vision of their patient.

Dr. Coney: Early Detection of a RAP lesion with ForeseeHome

Dr. Coney: What are some of the limitations of the Amsler Grid?

Dr. Coney: How did you integrate FSH into your plan/protocol to manage AMD patients?

Dr. Sheth: Asymptomatic Detection of CNV with ForeseeHome

Dr. Sheth: Do your patients feel reassured that you are remotely monitoring their vision?

Dr. Sheth: Why is early wet AMD detection important and what is the impact on visual acuity?


1. AREDS2-HOME Study Research Group. Ophthalmology. 2014;121(2):535-544

Coney

Joseph M. Coney, MD

Dr. Coney practices at Retina Associates of Cleveland and is actively involved in clinical research and teaching. He is a Senior Clinical Instructor at University Hospitals/Case Western Reserve University, where he completed his ophthalmology residency. Dr. Coney has been a clinical investigator in over 110 research studies of treatments for diabetic retinopathy, age-related macular degeneration, and other vitreoretinal diseases. He gives lectures locally, nationally, and internationally to both professional societies and community organizations.

Sheth

Veeral S. Sheth, MD, MBA, FACS

Dr. Sheth practices at University Retina in the Chicagoland area. In addition, he continues to teach physicians and students at the University of Illinois at Chicago. Dr. Sheth is actively involved in clinical research including national trials for age-related macular degeneration, retinal vascular occlusion, and diabetic retinopathy. His efforts in research have resulted in many peer-reviewed publications, meeting abstracts, and textbook chapters. He is the first author on the latest edition of the Massachusetts Eye & Ear Infirmary Review Manual for Ophthalmology.